Newsfeeds - Spark Newswire

1 minute read

Seagen Reports Last Patient Enrolled In Phase 2 MOUNTAINEER Trial Evaluating TUKYSA Regimen In HER2-Positive Metastatic Colorectal Cancer

Today, 8:04 AM

Seagen Inc. (NASDAQ:SGEN) today announced it completed patient enrollment in the phase 2 open-label MOUNTAINEER clinical trial, evaluating TUKYSA® (tucatinib) in combination with trastuzumab (Herceptin®) and as a

SGEN

1 minute read

RBC Capital Maintains Sector Perform on Seagen, Raises Price Target to $154

By vishwanath@benzinga.com

Today, 8:04 AM

RBC Capital analyst Kennen MacKay maintains Seagen (NASDAQ:SGEN) with a Sector Perform and raises the price target from $148 to $154.

SGEN

1 minute read

SVB Leerink Maintains Outperform on Seagen, Lowers Price Target to $190

By Benzinga Newsdesk

Today, 8:04 AM

SVB Leerink analyst Andrew Berens maintains Seagen (NASDAQ:SGEN) with a Outperform and lowers the price target from $192 to $190.

SGEN

1 minute read

FDA
News

Why Genmab’s Stock Is Trading Higher Today

By Benzinga Insights

Today, 8:04 AM

Genmab A/S (NASDAQ:GMAB) shares are trading higher after the company, along with Seagen Inc. (NASDAQ: SGEN), announced the FDA has granted accelerated approval to TIVDAKTM for the treatment of

GMAB

1 minute read

FDA
News

Why Seagen’s Stock Is Trading Higher Today

By Benzinga Insights

Today, 8:04 AM

Seagen (NASDAQ:SGEN) shares are trading higher after the company, along with Genmab A/S (NASDAQ: GMAB), announced the FDA has granted accelerated approval to TIVDAKTM for the treatment of adult patients with r

GMAB

6 minute read

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data

By Shanthi Rexaline

Today, 8:04 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)

ABSI

3 minute read

FDA
News

Seagen, Genmab Report FDA Accelerated Approval For TIVDAK In Previously Treated Recurrent, Metastatic Cervical Cancer

By Benzinga Newsdesk

Today, 8:04 AM

- TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor, a Protein Expressed on Cervical Cancer Cells - - New Monotherapy Approved for Use in a Cancer with Limited Treatment Options - BOTHELL,

GMAB

1 minute read

Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer

By Vandana Singh

Today, 8:04 AM

Seagen Inc (NASDAQ:SGEN) and Genmab A/S (NASDAQ:GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its…

GMAB

2 minute read

News

Seagen To Highlight Research From 16 Presentations Across Multiple Tumor Types At ESMO 2021

By Benzinga Newsdesk

Today, 8:04 AM

Seagen Inc. (NASDAQ:SGEN) today announced data and trials in progress from its diverse and growing portfolio of marketed and investigational therapies will be presented at the virtual European Society for Medical

SGEN

2 minute read

A Look Into Seagen’s Price Over Earnings

By Benzinga Insights

Today, 8:04 AM

SGEN